Cargando…
Leveraging cryoablation and checkpoint inhibitors for high-risk triple negative breast cancer
Breast cancer is the second most common cancer among women in the United States in which the standard of care treatment is surgery with adjunctive therapy. Cryoablation, which destroys the tumor using extremely cold temperatures while preserving the potential tumor antigens, is a promising alternati...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582696/ https://www.ncbi.nlm.nih.gov/pubmed/37860001 http://dx.doi.org/10.3389/fimmu.2023.1258873 |
_version_ | 1785122388814331904 |
---|---|
author | Sardela de Miranda, Flávia Castro, Maribel Remmert, Nicole Singh, Sharda P. Layeequr Rahman, Rakhshanda Melkus, Michael W. |
author_facet | Sardela de Miranda, Flávia Castro, Maribel Remmert, Nicole Singh, Sharda P. Layeequr Rahman, Rakhshanda Melkus, Michael W. |
author_sort | Sardela de Miranda, Flávia |
collection | PubMed |
description | Breast cancer is the second most common cancer among women in the United States in which the standard of care treatment is surgery with adjunctive therapy. Cryoablation, which destroys the tumor using extremely cold temperatures while preserving the potential tumor antigens, is a promising alternative to surgical resection. It is less invasive, cosmetically appeasing, cost-effective, and capable of contributing to the abscopal effect – the immune response targeting potential distant metastasis. However, to maximize the immunologic benefit of cryoablation in biologically high-risk breast cancers, combination with therapies that enhance immune activation, such as immune checkpoint inhibitors (ICIs) may be necessary. This mini review describes the fundamentals of cryoablation and treatment with ICIs, as well as discuss the caveats in both strategies and current clinical trials aimed to improve this approach to benefit patients. |
format | Online Article Text |
id | pubmed-10582696 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105826962023-10-19 Leveraging cryoablation and checkpoint inhibitors for high-risk triple negative breast cancer Sardela de Miranda, Flávia Castro, Maribel Remmert, Nicole Singh, Sharda P. Layeequr Rahman, Rakhshanda Melkus, Michael W. Front Immunol Immunology Breast cancer is the second most common cancer among women in the United States in which the standard of care treatment is surgery with adjunctive therapy. Cryoablation, which destroys the tumor using extremely cold temperatures while preserving the potential tumor antigens, is a promising alternative to surgical resection. It is less invasive, cosmetically appeasing, cost-effective, and capable of contributing to the abscopal effect – the immune response targeting potential distant metastasis. However, to maximize the immunologic benefit of cryoablation in biologically high-risk breast cancers, combination with therapies that enhance immune activation, such as immune checkpoint inhibitors (ICIs) may be necessary. This mini review describes the fundamentals of cryoablation and treatment with ICIs, as well as discuss the caveats in both strategies and current clinical trials aimed to improve this approach to benefit patients. Frontiers Media S.A. 2023-10-04 /pmc/articles/PMC10582696/ /pubmed/37860001 http://dx.doi.org/10.3389/fimmu.2023.1258873 Text en Copyright © 2023 Sardela de Miranda, Castro, Remmert, Singh, Layeequr Rahman and Melkus https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Sardela de Miranda, Flávia Castro, Maribel Remmert, Nicole Singh, Sharda P. Layeequr Rahman, Rakhshanda Melkus, Michael W. Leveraging cryoablation and checkpoint inhibitors for high-risk triple negative breast cancer |
title | Leveraging cryoablation and checkpoint inhibitors for high-risk triple negative breast cancer |
title_full | Leveraging cryoablation and checkpoint inhibitors for high-risk triple negative breast cancer |
title_fullStr | Leveraging cryoablation and checkpoint inhibitors for high-risk triple negative breast cancer |
title_full_unstemmed | Leveraging cryoablation and checkpoint inhibitors for high-risk triple negative breast cancer |
title_short | Leveraging cryoablation and checkpoint inhibitors for high-risk triple negative breast cancer |
title_sort | leveraging cryoablation and checkpoint inhibitors for high-risk triple negative breast cancer |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582696/ https://www.ncbi.nlm.nih.gov/pubmed/37860001 http://dx.doi.org/10.3389/fimmu.2023.1258873 |
work_keys_str_mv | AT sardelademirandaflavia leveragingcryoablationandcheckpointinhibitorsforhighrisktriplenegativebreastcancer AT castromaribel leveragingcryoablationandcheckpointinhibitorsforhighrisktriplenegativebreastcancer AT remmertnicole leveragingcryoablationandcheckpointinhibitorsforhighrisktriplenegativebreastcancer AT singhshardap leveragingcryoablationandcheckpointinhibitorsforhighrisktriplenegativebreastcancer AT layeequrrahmanrakhshanda leveragingcryoablationandcheckpointinhibitorsforhighrisktriplenegativebreastcancer AT melkusmichaelw leveragingcryoablationandcheckpointinhibitorsforhighrisktriplenegativebreastcancer |